2.54

0.20% 0.01

Poseida Therapeutics Inc (PSTX)

Overview News Price History Option Chain Financials Discussions Forecast

Poseida Therapeutics Inc stock is traded at $2.54, with a volume of 133.50K. It is up +0.20% in the last 24 hours and down -2.87% over the past month. Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Previous Close:

$2.53

Open:

$2.5

24h Volume:

133.50K

Relative Volume:

0.32

Market Cap:

$248.18M

Revenue:

$64.70M

Net Income/Loss:

$-123.43M

P/E Ratio:

-10.58

EPS:

-0.24

Net Cash Flow:

$-95.23M

1W Performance:

+3.47%

1M Performance:

-2.87%

6M Performance:

-11.67%

1Y Performance:

+3.47%

1-Day Range:

$2.48

$2.57

1-Week Range:

$2.32

$2.61

52-Week Range:

$1.87

$4.27

Poseida Therapeutics Inc Stock (PSTX) Company Profile

Name

Poseida Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

858-779-3100

Address

9390 TOWNE CENTRE DRIVE, SAN DIEGO

Employee

337

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PSTX's Discussions on Twitter

Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-04-23	Initiated	H.C. Wainwright	Buy
Jan-07-22	Initiated	Cantor Fitzgerald	Overweight
May-18-21	Initiated	BTIG Research	Buy
Aug-04-20	Initiated	BofA Securities	Buy
Aug-04-20	Initiated	Piper Sandler	Overweight
Aug-04-20	Initiated	William Blair	Outperform

View All

Poseida Therapeutics Inc Stock (PSTX) Latest News

Nov 01, 2024

Poseida Therapeutics (STU:2RZ) Degree of Operating Leverage : -9.17 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024

Oct 30, 2024

Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Oct 30, 2024

Oct 26, 2024

Poseida Therapeutics Receives Regenerative Medicine Advanced The - GuruFocus.com

Oct 26, 2024

Oct 24, 2024

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire

Oct 24, 2024

Oct 19, 2024

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% - Simply Wall St

Oct 19, 2024

Oct 18, 2024

Third development candidate nominated under Poseida and Roche’s allogeneic CAR T collaboration - BioWorld Online

Oct 18, 2024

Oct 17, 2024

Poseida shares hold as analyst reiterates buy rating on MM study - Investing.com

Oct 17, 2024

Poseida Nominates New Development Candidate Under Its Collaboration With Roche - Contract Pharma

Oct 17, 2024

Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright - MarketBeat

Oct 17, 2024

Poseida advances with new CAR-T therapy candidate - Investing.com

Oct 17, 2024

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - StockTitan

Oct 17, 2024

Oct 16, 2024

Quarterly Metrics: Quick and Current Ratios for Poseida Therapeutics Inc (PSTX) - The Dwinnex

Oct 16, 2024

Oct 15, 2024

Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World

Oct 15, 2024

Oct 14, 2024

The Anatomy Of Astellas And Poseida's CAR-T Deal - In Vivo

Oct 14, 2024

Oct 10, 2024

PSTXPoseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 10, 2024

Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™

Oct 10, 2024

Oct 07, 2024

Ratio Examination: Poseida Therapeutics Inc (PSTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 07, 2024